DOCSLIB.ORG

Drug-Induced Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

INDEX Figures and tables are indicated by “f” and “t” following page numbers. AAD. See Antibiotic-associated diarrhea delirium and, 326t morbidity and mortality for, 956 AAN (American Academy of Neurology), 264–265 hirsutism and, 194, 195t, 199t overview, 955 Abacavir neutropenia/agranulocytosis and, 1089t patient education on, 957 acidosis and, 1003t ototoxicity and, 1234t prevention of, 956–957 allergic and hypersensitivity reactions to, 75t, peripheral neuropathy and, 281t risk factors for, 956 88, 112 photosensitivity and, 144t Acute kidney injury (AKI), 941–960 anxiety and, 400t, 403 tardive dyskinesia and, 265 acute interstitial nephritis, 955–957 cutaneous diseases and, 111t, 113t taste disorders and, 1259t, 1261t acute tubular necrosis, 949–955 genetic variability and, 16t visual disturbances and, 296t community-acquired, 941–942, 944 genetic variations affecting, 36t Acetohydroxamic acid, 1066t, 1070t defined, 941 glucose/insulin dysregulation and, 690 Acetylcholine glomerulonephritis, 958–960 human leukocyte antigen and, 37, 38 cognitive disorders and, 359, 360 hemodynamic-mediated, 942–949 malignant hyperthermia and, 1186 delirium and, 329 hospital-acquired, 941–942 myocardial ischemia/acute coronary syndromes myocardial ischemia/acute coronary syndromes nephrolithiasis, 957–958 and, 472t and, 473t Acute lymphoblastic leukemia (ALL), 1283, 1286, nausea/vomiting and, 909t myopathy and, 1153 1291 neutropenia/agranulocytosis and, 1089t psychosis and, 418 Acute myeloid leukemia (AML), 1283–1287, oral erythema multiforme and, 1266t sexual dysfunction and, 766 1289–1292 osteoporosis/osteomalacia and, 1127 in sleep cycles, 349 Acute tubular necrosis (ATN), 949–955 ototoxicity and, 1234t Acetylcholinesterase inhibitors, 335 causative agents of, 943t, 949–950 pharmacogenomic tests for, 35 Acetylcysteine, 440, 1243 clinical presentation of, 946t, 951 Abatacept, 1270t Acetyl-L-carnitine, 286, 287t, 288 differential diagnosis of, 951 Abciximab, 238t, 239, 1029t, 1050t, 1052t, 1053 Acetylsalicylic acid. See Aspirin epidemiology of, 950 Abiraterone, 698t, 836t Acid–base disorders. See Acidosis; Alkalosis management of, 955 Absolute neutrophil count (ANC), 1087, 1092, 1094, Acidosis, 1001–1011 mechanisms of, 950–951 1096 anion gap metabolic, 1002t, 1004t, 1007t morbidity and mortality for, 952 ABVD regimen, 1285, 1286, 1291 causative agents of, 1001, 1002–1003t patient education on, 955 Acebutolol clinical presentation of, 1005–1007, 1006t prevention of, 952–955 alopecia and, 168t differential diagnosis of, 1006, 1007t risk factors for, 951–952 hypotension and, 632t, 638t epidemiology of, 1001 Acyclovir, 168t, 196t, 944–945t, 957, 967, 1188t, photosensitivity and, 144t ketoacidosis, 1002t, 1004t 1191, 1295 sinus bradycardia/atrioventricular block and, 577t lactic, 1002t, 1004, 1004t, 1007–1008, 1010–1011 Adalimumab systemic lupus erythematosus and, 124t, 128t, management of, 1008–1011, 1009f, 1010t, 1011f alopecia and, 173t 132 mechanisms of, 1001, 1004–1005, 1004t depression and, 383 ACE inhibitors. See Angiotensin-converting enzyme morbidity and mortality for, 1007 hepatic/cholestatic diseases and, 852t inhibitors patient education on, 1011 interstitial lung disease/pulmonary fibrosis and, Acenocoumarol, 1029t prevention of, 1007–1008, 1008t 433t Acetaminophen renal tubular, 1003–1004t, 1004, 1006, 1010, 1011f oral erythema multiforme and, 1266t acidosis and, 1002t respiratory, 1001, 1003–1004t, 1005–1007, oral lichenoid reactions and, 1270t asthma/bronchospasm and, 452t, 453, 455t, 461 1007–1008t, 1010–1011 serum sickness-like reactions and, 1193t chronic kidney disease and, 968–970, 973, 976 risk factors for, 1007, 1008t sexual dysfunction and, 761t cutaneous diseases and, 101, 102–103t Acitretin, 166, 173t, 791, 1273 skin cancer and, 1297 drug interactions with, 39 Acne, 102t, 105, 107t, 108, 114, 114t, 384 systemic lupus erythematosus and, 126t hemolytic anemia and, 1105t ACOG (American College of Obstetricians and thyroid diseases and, 698–699t, 701t, 710 hepatic/cholestatic diseases and, 846t, 853, 856, Gynecologists), 626, 1302, 1303 valvular/pericardial heart disease and, 660t, 662 864–866 Aconite, 573t visual disturbances and, 296t hypothermia and, 1216 Aconite alkaloids, 524–525t, 525 Addison disease, 734–735 myocardial ischemia/acute coronary syndromes ACTH. See Adrenocorticotropic hormone Adefovir, 966, 966t, 970t, 1003t, 1050t and, 489 Actinomycin, 847t, 907t Adenosine neutropenia/agranulocytosis and, 1089t Activated charcoal, 245, 580, 587–588, 701t, 1039 acute kidney injury and, 951, 953 oral erythema multiforme and, 1266t Acute akathisia. See Akathisia atrial fibrillation/atrial flutter and, 581, 582–583t, ototoxicity and, 1233, 1234–1235t Acute coronary syndromes. See Myocardial 583–586, 585t pancreatitis and, 878t, 881 ischemia/acute coronary syndromes atrial tachycardia and, 591 peripheral neuropathy and, 288 Acute dystonia. See Dystonia AV node re-entrant tachycardia and, 594 smoking and, 32 Acute hypertension, 232, 240 hypotension and, 644 teratogenicity of, 1321, 1326 Acute interstitial nephritis (AIN), 955–957 monomorphic ventricular tachycardia and, thrombocytopenia and, 1050t, 1052t causative agents of, 943t, 956 524–525t, 525–526 vaginal bleeding disorders and, 797 clinical presentation of, 946t, 956 myocardial ischemia/acute coronary syndromes Acetate, 1013–1014t differential diagnosis of, 956 and, 472t, 477t, 479 Acetazolamide epidemiology of, 956 sinus bradycardia/atrioventricular block and, acidosis and, 1003t management of, 957 570t, 573t, 577–579 aplastic anemia and, 1100t mechanisms of, 945t, 956 structural similarities with hydralazine, 127 1343 Unauthenticated | Downloaded 09/27/21 02:57 PM UTC INDEX ADHD (attention deficit/hyperactivity disorder) differential diagnosis of, 257, 257t Alendronate agents, 219t, 221–222, 401 epidemiology of, 254–255 atrial fibrillation/atrial flutter and, 581, 582t, 584 Adjuvant chemotherapy, 1167–1169t, 1172, 1173t management of, 258–259, 259t hepatic/cholestatic diseases and, 848t Adolescents. See Pediatric patients mechanisms of, 255–256, 256t osteonecrosis of jaw and, 1274t Ado-trastuzumab, 169t, 836t morbidity and mortality for, 258 osteoporosis/osteomalacia and, 1129t, 1130 Adrenal diseases. See Hypothalamic, pituitary, and overview, 253–254 upper gastrointestinal ulceration and, 812–814, adrenal diseases patient education on, 259 816, 818 Adrenergic β-receptor blockers. See β-adrenergic prevention of, 258, 258t visual disturbances and, 296t receptor blockers (β-blockers) risk factors for, 258, 258t Alfalfa, 144t Adrenocorticotropic hormone (ACTH) AKI. See Acute kidney injury Alfentanil, 906t Cushing syndrome and, 731t, 732 Alanine aminotransferase (ALT), 859, 862, 868, Alfuzosin, 296t, 472t, 632t, 639t, 1050t, 1234t cutaneous diseases and, 108 1058 Aliskiren, 633t, 638t, 942 hirsutism and, 194, 195t, 199t Albiglutide, 879t Alitretinoin, 144t hypersensitivity reactions to, 77t Albumin, 364, 784, 787, 868–871, 1242 Alkaline phosphatase (ALP), 859, 862 pancreatitis and, 882 Albuterol Alkalosis, 1012–1018 primary adrenal insufficiency and, 735 acidosis and, 1002t causative agents of, 1012, 1013t secondary adrenal insufficiency and, 735, 741 anxiety and, 404 clinical presentation of, 1014–1015, 1015t stimulation test for, 738 atrial fibrillation/atrial flutter and, 582t, 584 differential diagnosis of, 1015, 1016t synthesis of, 729 atrial tachycardia and, 588–589t, 589 epidemiology of, 1012 Adverse drug reactions (ADRs). See also Drug- AV node re-entrant tachycardia and, 592–594, management of, 1016–1017, 1018f, 1018t induced diseases 592–594t mechanisms of, 1012–1014, 1014t allergies. See Drug allergies myocardial ischemia/acute coronary syndromes morbidity and mortality for, 1015–1016 categorization of, 23, 59–60 and, 473t patient education on, 1017 causality/correlation in, 23 psychosis and, 416t, 418t respiratory, 1012–1017, 1013–1016t differential diagnosis of, 51, 63–65 teratogenicity of, 1320 risk factors for, 1015, 1017t documentation of, 65–66 visual disturbances and, 296t Alkylating agents drug–drug interactions, 38–40, 39t Alcohol use chemotherapy-induced anemia and, 1101t, 1109, food–drug interactions, 40–41 anxiety and, 409 1109t gender differences in, 31–32 atrial fibrillation/atrial flutter and, 581, 582–583t, infertility and, 783t, 786t, 800 hospital admissions due to, 28 584–586, 585–586t leukemia and, 1284, 1289, 1290 hypersensitivity. See Drug hypersensitivity Brugada syndrome and, 547, 547t, 549 neutropenia/agranulocytosis and, 1087, 1091 reactions (DHRs) cognitive disorders and, 362 sexual dysfunction and, 767, 770 manifestations of, 19 delirium and, 326t, 330, 337 vaginal bleeding disorders and, 782t, 785t in medication histories, 60, 62 diarrhea and, 825, 827 ALL (acute lymphoblastic leukemia), 1283, 1286, mortality associated with, 29 duration of detection in urine, 420t 1291 Naranjo Scale for, 64, 65, 65t gout/hyperuricemia and, 1139, 1146 Allergic-mediated blood disorders, 75t, 80, 83–84, in new drug approval process, 48 heart failure and, 516 83t 9 points of consideration for, 63–64 hepatic/cholestatic diseases and, 864 Allergic reactions. See Drug allergies postmarketing surveillance for. See Postmarketing hyperprolactinemia and, 744t Allodynia, 1141 surveillance hypertrichosis and, 197t Allopurinol prevalence of, 4 hypotension and, 643, 648 acute kidney injury and, 943–944t, 957 probability ratings for, 64, 64–65t, 65 intracerebral hemorrhage and, 238–240, 238t, allergic and hypersensitivity reactions to, 74–75t, quantitative
Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000

    List of New Drugs Approved in India from 1991 to 2000

    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
  • NIH Public Access Author Manuscript Bioorg Med Chem

    NIH Public Access Author Manuscript Bioorg Med Chem

    NIH Public Access Author Manuscript Bioorg Med Chem. Author manuscript; available in PMC 2013 February 01. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Bioorg Med Chem. 2012 February 1; 20(3): 1291–1297. doi:10.1016/j.bmc.2011.12.019. Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents Kwakye Pepraha, Xue Y. Zhua, Suresh V. K. Eyunnia, Vincent Setolab, Bryan L. Rothb, and Seth Y. Ablordeppey*,a aDivision of Basic Pharmaceutical Sciences, Florida A&M University, College of Pharmacy and Pharmaceutical Sciences, Tallahassee, FL 32307, USA bDepartment of Pharmacology, Medicinal Chemistry and Psychiatry, University of North Carolina at Chapel Hill, School of Medicine, NC 27599, USA Abstract Using haloperidol as a scaffold, new agents were designed to investigate the structural contributions of various groups to binding at CNS receptors associated with atypical antipsychotic pharmacology. It is clear that each pharmacophoric group, the butyrophenone, the piperidine and the 4-chlorophenyl moieties contributes to changes in binding to the receptors of interest. This strategy has resulted in the identification of several new agents, compounds 16, 18, 19, 23, 24 and 25, with binding profiles which satisfy our stated criteria for agents to act as potential atypical antipsychotics. This research demonstrates that haloperidol can serve as a useful lead in the identification and design of new agents that target multiple receptors
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    2D6 Substrates 2D6 Inhibitors 2D6 Inducers

    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • Research in Your Backyard Developing Cures, Creating Jobs

    Research in Your Backyard Developing Cures, Creating Jobs

    Research in Your Backyard Developing Cures, Creating Jobs PHARMACEUTICAL CLINICAL TRIALS IN ILLINOIS Dots show locations of clinical trials in the state. Executive Summary This report shows that biopharmaceutical research com- Quite often, biopharmaceutical companies hire local panies continue to be vitally important to the economy research institutions to conduct the tests and in Illinois, and patient health in Illinois, despite the recession. they help to bolster local economies in communities all over the state, including Chicago, Decatur, Joliet, Peoria, At a time when the state still faces significant economic Quincy, Rock Island, Rockford and Springfield. challenges, biopharmaceutical research companies are conducting or have conducted more than 4,300 clinical For patients, the trials offer another potential therapeutic trials of new medicines in collaboration with the state’s option. Clinical tests may provide a new avenue of care for clinical research centers, university medical schools and some chronic disease sufferers who are still searching for hospitals. Of the more than 4,300 clinical trials, 2,334 the medicines that are best for them. More than 470 of the target or have targeted the nation’s six most debilitating trials underway in Illinois are still recruiting patients. chronic diseases—asthma, cancer, diabetes, heart dis- ease, mental illnesses and stroke. Participants in clinical trials can: What are Clinical Trials? • Play an active role in their health care. • Gain access to new research treatments before they In the development of new medicines, clinical trials are are widely available. conducted to prove therapeutic safety and effectiveness and compile the evidence needed for the Food and Drug • Obtain expert medical care at leading health care Administration to approve treatments.
  • Properties and Units in Clinical Pharmacology and Toxicology

    Properties and Units in Clinical Pharmacology and Toxicology

    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
  • Appendix 13C: Clinical Evidence Study Characteristics Tables

    Appendix 13C: Clinical Evidence Study Characteristics Tables

    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
  • Sibelium 5 Mg Tablets

    Sibelium 5 Mg Tablets

    PACKAGE LEAFLET: INFORMATION FOR THE USER Sibelium 5 mg Tablets flunarizine Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. In this leaflet: 1. What Sibelium is and what it is used for 2. What you need to know before you take Sibelium 3. How to take Sibelium 4. Possible side effects 5. How to store Sibelium 6. Contents of the pack and other information 1. WHAT SIBELIUM IS AND WHAT IT IS USED FOR What is Sibelium? Sibelium tablets contain flunarizine. They belong to a group of medicines known as calcium channel blockers, which work by preventing the narrowing of blood vessels. What is it used for? Sibelium Tablets are for use in adults. They have been prescribed for you to help your migraine-type headaches. If you take Sibelium Tablets regularly they can help you get fewer headaches, or less painful headaches. They can stop some migraine attacks starting and help make other attacks less severe. While you are taking Sibelium Tablets, your doctor will review your treatment at regular intervals in order to assess your response to the medicine.
  • Tall Man Lettering List REPORT DECEMBER 2013 1

    Tall Man Lettering List REPORT DECEMBER 2013 1

    Tall Man Lettering List REPORT DECEMBER 2013 1 TALL MAN LETTERING LIST REPORT WWW.HQSC.GOVT.NZ Published in December 2013 by the Health Quality & Safety Commission. This document is available on the Health Quality & Safety Commission website, www.hqsc.govt.nz ISBN: 978-0-478-38555-7 (online) Citation: Health Quality & Safety Commission. 2013. Tall Man Lettering List Report. Wellington: Health Quality & Safety Commission. Crown copyright ©. This copyright work is licensed under the Creative Commons Attribution-No Derivative Works 3.0 New Zealand licence. In essence, you are free to copy and distribute the work (including other media and formats), as long as you attribute the work to the Health Quality & Safety Commission. The work must not be adapted and other licence terms must be abided. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nd/3.0/nz/ Copyright enquiries If you are in doubt as to whether a proposed use is covered by this licence, please contact: National Medication Safety Programme Team Health Quality & Safety Commission PO Box 25496 Wellington 6146 ACKNOWLEDGEMENTS The Health Quality & Safety Commission acknowledges the following for their assistance in producing the New Zealand Tall Man lettering list: • The Australian Commission on Safety and Quality in Health Care for advice and support in allowing its original work to be either reproduced in whole or altered in part for New Zealand as per its copyright1 • The Medication Safety and Quality Program of Clinical Excellence Commission, New South
  • Tanibirumab (CUI C3490677) Add to Cart

    Tanibirumab (CUI C3490677) Add to Cart

    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
  • Oral Anticoagulants

    Oral Anticoagulants

    4/26/2018 Disclosure • Kelsey Gander, PharmD, BCACP Direct Oral Anticoagulants: – Declares no financial relationships pertinent to this session When to Use and How to Choose – Declares off-label use of medication will not be discussed during this presentation. Kelsey Gander, PharmD, BCACP Minnesota Academy of Physician Assistants Conference May 11th, 2018 Abbreviations Objectives • DOAC= direct oral anticoagulant 1) Compare and contrast the efficacy and safety • VTE= venous thromboembolism • DVT= deep vein thrombosis of direct oral anticoagulants (DOACs) to • PE= pulmonary embolism warfarin • A-fib, AF= atrial fibrillation 2) Identify which anticoagulant would be most • ESRD= end stage renal disease appropriate for a given patient • ACC= American College of Cardiology • AHA= American Heart Association 3) Recognize when it would not be appropriate • HRS= Heart Rhythm Society to use a DOAC • BID= twice daily Appropriate Abbreviations Patient Case JJ is a 66 y/o male who was hospitalized for pulmonary • NOAC embolism and initiated on anticoagulant therapy one week – Novel Oral Anticoagulant ago. – Chief complaint: – Non-Vitamin K Oral Anticoagulant • Presents to clinic today for INR check, post-hospital discharge follow- up • TSOAC – Past medical history: • Hypertension, hyperlipidemia, osteoarthritis, erectile dysfunction, – Target Specific Oral Anticoagulant BPH, type 2 diabetes, peripheral artery disease – Home medications • DOAC • Acetaminophen 650mg po every 6 hours PRN – Direct Oral Anticoagulant • Diazepam 5mg po at bedtime PRN anxiety
  • Mechanisms of Action of Antipsychotic Drugs Of

    Mechanisms of Action of Antipsychotic Drugs Of

    302 Current Neuropharmacology, 2009, 7, 302-314 Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I R. Miller* Otago Centre for Theoretical Studies in Psychiatry and Neuroscience (OCTSPAN), Department of Anatomy and Struc- tural Biology, School of Medical Sciences, University of Otago, P.O.Box 913, Dunedin, New Zealand Abstract: Many issues remain unresolved about antipsychotic drugs. Their therapeutic potency scales with affinity for dopamine D2 receptors, but there are indications that they act indirectly, with dopamine D1 receptors (and others) as pos- sible ultimate targets. Classical neuroleptic drugs disinhibit striatal cholinergic interneurones and increase acetyl choline release. Their effects may then depend on stimulation of muscarinic receptors on principle striatal neurones (M4 recep- tors, with reduction of cAMP formation, for therapeutic effects; M1 receptors for motor side effects). Many psychotic pa- tients do not benefit from neuroleptic drugs, or develop resistance to them during prolonged treatment, but respond well to clozapine. For patients who do respond, there is a wide (>ten-fold) range in optimal doses. Refractoriness or low sensitiv- ity to antipsychotic effects (and other pathologies) could then arise from low density of cholinergic interneurones. Clozap- ine probably owes its special actions to direct stimulation of M4 receptors, a mechanism available when indirect action is lost. Key Words: Antipsychotic drugs, neuroleptic drugs, cholinergic interneurones, D1 receptors, D2 receptors, muscarinic M1 receptors, muscarinic M4 receptors, neuroleptic threshold, atypical antipsychotic agents. 1. INTRODUCTION these drugs. Guidelines for dosage, and dose equivalences between different drugs have been based on group averages The first antipsychotic drug - chlorpromazine - was dis- derived from dose-finding trials.